Daniel Birnbaum

List of Publications by Year
in descending order

229	23,377	10351 72	8370 147
papers	citations	h-index	g-index

237	237	237	28905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137.	2.6	10
2	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	2.3	6
3	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
4	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death and Disease, 2022, 13, 96.	2.7	13
5	Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. Cancers, 2022, 14, 932.	1.7	5
6	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	3.3	12
7	CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response. Cancers, 2022, 14, 1306.	1.7	3
8	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of Personalized Medicine, 2022, 12, 655.	1.1	2
9	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. Cancers, 2022, 14, 2275.	1.7	0
10	Overcoming Resistance to Antiâ€“Nectin-4 Antibody-Drug Conjugate. Molecular Cancer Therapeutics, 2022, 21, 1227-1235.	1.9	13
11	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2314-2325.	3.2	10
12	EFA6B regulates a stop signal for collective invasion in breast cancer. Nature Communications, 2021, 12, 2198.	5.8	2
13	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	3.6	24
14	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. Npj Breast Cancer, 2021, 7, 48.	2.3	3
15	WEE1 Dependency and Pejorative Prognostic Value in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2101030.	5.6	8
16	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	2.1	22
17	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, 2021, 159, 205-214.	1.3	7
18	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer, 2020, 59, 30-39.	1.5	17

#	Article	IF	Citations
19	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. In Vivo, 2020, 34, 177-184.	0.6	10
20	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	2.1	23
21	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancerâ€"Letter. Clinical Cancer Research, 2020, 26, 5539-5539.	3.2	0
22	Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. Haematologica, 2020, 105, e340-e342.	1.7	5
23	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. Cancers, 2020, 12, 2470.	1.7	14
24	SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, 2020, 27, 438-449.	3.6	39
25	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood Cancer Journal, 2020, 10, 64.	2.8	18
26	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	0.6	28
27	EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. Blood, 2020, 135, 2004-2009.	0.6	9
28	The therapeutic response of ER+/HER2â˜' breast cancers differs according to the molecular Basal or Luminal subtype. Npj Breast Cancer, 2020, 6, 8.	2.3	27
29	Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 206-214.	0.6	3
30	Gains of EPOR and ERG genes in adult erythroleukaemia. British Journal of Haematology, 2020, 189, e174-e177.	1.2	4
31	ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. Journal of Cellular Biochemistry, 2020, 121, 4870-4886.	1.2	0
32	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. Cancers, 2019, 11, 1158.	1.7	6
33	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clinical Epigenetics, 2019, 11, 141.	1.8	11
34	A genomeâ€wide <scp>RNA</scp> i screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Molecular Medicine, 2019, 11, e9930.	3.3	27
35	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, 2019, 11, 774.	1.7	23
36	PARP1 expression in soft tissue sarcomas is a poorâ€prognosis factor and a new potential therapeutic target. Molecular Oncology, 2019, 13, 1577-1588.	2.1	15

#	Article	IF	Citations
37	Genomic characterization of metastatic breast cancers. Nature, 2019, 569, 560-564.	13.7	448
38	XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. Journal of Clinical Medicine, 2019, 8, 596.	1.0	23
39	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, 2019, 11, 665.	1.7	25
40	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers, 2019, 11, 497.	1.7	61
41	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. British Journal of Cancer, 2019, 120, 931-940.	2.9	13
42	High Response to Cetuximab in a Patient With EGFR-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2019, 3, 1-8.	1.5	5
43	JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. Hematological Oncology, 2019, 37, 201-201.	0.8	0
44	MARCKS protein overexpression is associated with poor prognosis in male breast cancer. Cancer Biomarkers, 2019, 26, 513-522.	0.8	8
45	Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO Precision Oncology, 2019, 3, 1-9.	1.5	0
46	Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade. Annals of Oncology, 2019, 30, 342-343.	0.6	3
47	Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1289-1293.	0.6	4
48	Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight, 2019, 4, .	2.3	31
49	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 248-255.	3.3	20
50	â€œWnt/Î²-Catenin in GISTâ€â€”Letter. Molecular Cancer Therapeutics, 2018, 17, 327-328.	1.9	4
51	The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. Annals of Oncology, 2018, 29, 459-465.	0.6	24
52	Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 330-338.	2.0	49
53	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	2
54	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, 2018, 9, 33762-33777.	0.8	17

#	Article	IF	Citations
55	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. British Journal of Cancer, 2018, 119, 1383-1391.	2.9	54
56	Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. International Journal of Molecular Sciences, 2018, 19, 41.	1.8	7
57	Mutation of FOP/FGFR1OP in mice recapitulates human short rib-polydactyly ciliopathy. Human Molecular Genetics, 2018, 27, 3377-3391.	1.4	15
58	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. Cell Reports, 2017, 18, 2256-2268.	2.9	111
59	A stemness-related ZEB1â€“MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	15.2	131
60	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nature Chemistry, 2017, 9, 1025-1033.	6.6	423
61	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Pancreas, 2017, 46, e29-e31.	0.5	7
62	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia, 2017, 19, 564-573.	2.3	25
63	Fifteen years of research on oralâ€“facialâ€“digital syndromes: from 1 to 16 causal genes. Journal of Medical Genetics, 2017, 54, 371-380.	1.5	85
64	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals of Oncology, 2017, 28, 769-776.	0.6	77
65	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica, 2017, 102, e11-e14.	1.7	42
66	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomasâ€”Letter. Molecular Cancer Therapeutics, 2017, 16, 2324-2324.	1.9	2
67	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. Blood Cancer Journal, 2017, 7, e594-e594.	2.8	10
68	Flick the cancer stem cells' switch to turn cancer off. Molecular and Cellular Oncology, 2017, 4, e1319896.	0.3	0
69	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine, 2017, 15, 170.	2.3	64
70	Validation and comparison of the molecular classifications of pancreatic carcinomas. Molecular Cancer, 2017, 16, 168.	7.9	38
71	MARCKS protein overexpression in inflammatory breast cancer. Oncotarget, 2017, 8, 6246-6257.	0.8	27
72	De-repression of the RAC activator ELMO1 in cancer stem cells drives progression of TGFÎ²-deficient squamous cell carcinoma from transition zones. ELife, 2017, 6, .	2.8	12

#	Article	IF	Citations
73	Epigenetically centered evolution in an example of myeloid malignancy. American Journal of Hematology, 2016, 91, E361-2.	2.0	0
74	A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers. Molecular and Cellular Oncology, 2016, 3, e1232186.	0.3	5
75	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. Developmental Cell, 2016, 37, 311-325.	3.1	63
76	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nature Communications, 2016, 7, 12222.	5.8	113
77	SPAG5: the ultimate marker of proliferation in early breast cancer?. Lancet Oncology, The, 2016, 17, 863-865.	5.1	11
78	Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2â€“JNK signalling in breast cancer. Nature Communications, 2016, 7, 10318.	5.8	85
79	Breast cancer stem cells programs: enter the (non)-code. Briefings in Functional Genomics, 2016, 15, 186-199.	1.3	6
80	OFIP/KIAA0753 forms a complex with OFD1 and FOR20 at pericentriolar satellites and centrosomes and is mutated in one individual with oral-facial-digital syndrome. Human Molecular Genetics, 2016, 25, 497-513.	1.4	42
81	Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia, 2016, 30, 966-970.	3.3	31
82	Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget, 2016, 7, 71198-71210.	0.8	81
83	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441.	0.8	11
84	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7, 18531-18540.	0.8	38
85	Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219.	0.8	69
86	Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. Journal of Translational Medicine, 2015, 13, 138.	1.8	38
87	Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 2015, 6, 5449-5464.	0.8	424
88	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519.	0.8	105
89	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292.	2.8	21
90	Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML). Leukemia, 2015, 29, 500-502.	3.3	10

#	Article	IF	Citations
91	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment, 2015, 154, 495-508.	1.1	52
92	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget, 2015, 6, 8388-8396.	0.8	69
93	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 2014, 9, e104302.	1.1	43
94	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843.	1.1	53
95	The Functional Landscape of Hsp27 Reveals New Cellular Processes such as DNA Repair and Alternative Splicing and Proposes Novel Anticancer Targets. Molecular and Cellular Proteomics, 2014, 13, 3585-3601.	2.5	65
96	EFA6B Antagonizes Breast Cancer. Cancer Research, 2014, 74, 5493-5506.	0.4	25
97	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. American Journal of Hematology, 2014, 89, 604-609.	2.0	36
98	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology, 2014, 25, 358-365.	0.6	82
99	Brief Reports: A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome. Stem Cells, 2014, 32, 3031-3036.	1.4	33
100	ESPL1 is a candidate oncogene of luminal B breast cancers. Breast Cancer Research and Treatment, 2014, 147, 51-59.	1.1	51
101	Genomic profiling of inflammatory breast cancer: A review. Breast, 2014, 23, 538-545.	0.9	46
102	Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Reports, 2014, 2, 78-91.	2.3	854
103	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica, 2014, 99, 37-45.	1.7	38
104	Signaling pathway switch in breast cancer. Cancer Cell International, 2013, 13, 66.	1.8	25
105	ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. Cancer Research, 2013, 73, 7290-7300.	0.4	103
106	Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets. Journal of Immunology, 2013, 190, 2424-2436.	0.4	84
107	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	0.8	462
108	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	3.2	130

#	Article	IF	Citations
109	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	3.3	102
110	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. Clinical Cancer Research, 2013, 19, 6520-6531.	3.2	122
111	Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Annals of Oncology, 2013, 24, 625-632.	0.6	28
112	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, 2013, 98, 576-583.	1.7	9
113	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	0.6	169
114	Gene Expression Profiling of Solitary Fibrous Tumors. PLoS ONE, 2013, 8, e64497.	1.1	21
115	MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells. PLoS Genetics, 2012, 8, e1002751.	1.5	150
116	The emerging role of the TGFÎ² tumor suppressor pathway in pancreatic cancer. Cell Cycle, 2012, 11, 683-686.	1.3	12
117	Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Cell Cycle, 2012, 11, 3141-3142.	1.3	4
118	â€œStealthâ€•tumors. OncoImmunology, 2012, 1, 366-368.	2.1	14
119	p53 and cancer stem cells: The mevalonate connexion. Cell Cycle, 2012, 11, 2583-2584.	1.3	21
120	Genomic Grade Index predicts postoperative clinical outcome of GIST. British Journal of Cancer, 2012, 107, 1433-1441.	2.9	19
121	Basal Breast Cancer: A Complex and Deadly Molecular Subtype. Current Molecular Medicine, 2012, 12, 96-110.	0.6	173
122	Mutations and deletions of ARID1A in breast tumors. Oncogene, 2012, 31, 4255-4256.	2.6	52
123	Myeloid malignancies: mutations, models and management. BMC Cancer, 2012, 12, 304.	1.1	116
124	A refined molecular taxonomy of breast cancer. Oncogene, 2012, 31, 1196-1206.	2.6	221
125	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. PLoS ONE, 2012, 7, e37943.	1.1	34
126	Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer. PLoS ONE, 2012, 7, e43409.	1.1	4

#	Article	IF	Citations
127	Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target. Stem Cells, 2012, 30, 1327-1337.	1.4	120
128	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	0.6	220
129	Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. Journal of Hematology and Oncology, 2012, 5, 12.	6.9	226
130	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. Journal of Pathology, 2012, 227, 267-269.	2.1	2
131	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer, 2012, 51, 743-755.	1.5	139
132	Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment, 2012, 132, 1035-1047.	1.1	14
133	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study. , 2012, , 225-242.		0
134	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. Breast Cancer Research, 2011, 13, R109.	2.2	24
135	ASXL1 (additional sex combs like 1 (Drosophila)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
136	Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene, 2011, 30, 3862-3874.	2.6	52
137	Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition. Cancer Research, 2011, 71, 6621-6632.	0.4	114
138	A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 2011, 126, 407-420.	1.1	231
139	Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2011, 127, 363-373.	1.1	11
140	Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, 2011, 10, 86.	7.9	46
141	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine, 2011, 3, .	3.3	1
142	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine, 2011, 3, 153-166.	3.3	126
143	Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes and Cancer, 2011, 50, 456-465.	1.5	107
144	Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e33-e33.	2.8	36

#	Article	IF	Citations
145	Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2011, 364, 482-485.	13.9	14
146	Breast tumor microenvironment: In the eye of the cytokine storm. Cell Cycle, 2011, 10, 2421-2421.	1.3	7
147	Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer Journal, 2011, 1, e18-e18.	2.8	17
148	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation, 2011, 121, 3609-3622.	3.9	524
149	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, 2011, 6, e16950.	1.1	57
150	Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, 2011, 6, e27656.	1.1	143
151	Cancer stem cells: Just sign here!. Cell Cycle, 2010, 9, 227-232.	1.3	3
152	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.	1.1	140
153	Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, 2010, 10, 539.	1.1	136
154	Gene expression profiling of inflammatory breast cancer. Cancer, 2010, 116, 2783-2793.	2.0	45
155	Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, 2010, 85, 717-719.	2.0	46
156	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 365-375.	1.2	199
157	Myelodysplastic syndromes: lost between two states?. Leukemia, 2010, 24, 1-5.	3.3	38
158	Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 2010, 24, 469-473.	3.3	106
159	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia, 2010, 24, 1539-1541.	3.3	7
160	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010, 24, 1094-1096.	3.3	225
161	Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. Journal of Cell Science, 2010, 123, 2391-2401.	1.2	61
162	Aldehyde Dehydrogenase 1â€“Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research, 2010, 16, 45-55.	3.2	646

#	Article	IF	Citations
163	The CINSARC signature: Prognostic and predictive of response to chemotherapy?. Cell Cycle, 2010, 9, 4025-4027.	1.3	12
164	Targeting breast cancer stem cells: fishing season open!. Breast Cancer Research, 2010, 12, 312.	2.2	11
165	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation, 2010, 120, 485-497.	3.9	658
166	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	1.7	234
167	A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells. Molecular Cancer Research, 2009, 7, 402-414.	1.5	27
168	Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle, 2009, 8, 3297-3302.	1.3	193
169	The centrosomal FOP protein is required for cell cycle progression and survival. Cell Cycle, 2009, 8, 1217-1227.	1.3	34
170	Breast cancer stem cells: tools and models to rely on. BMC Cancer, 2009, 9, 202.	1.1	105
171	How different are luminal A and basal breast cancers?. International Journal of Cancer, 2009, 124, 1338-1348.	2.3	51
172	A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell International, 2009, 9, 5.	1.8	13
173	Distant metastasis: not out of reach any more. Journal of Biology, 2009, 8, 28.	2.7	16
174	Mutations of polycombâ€associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800.	1.2	537
175	Alterations of NFIA in chronic malignant myeloid diseases. Leukemia, 2009, 23, 583-585.	3.3	17
176	Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia, 2009, 23, 85-94.	3.3	49
177	Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, 2009, 23, 2183-2186.	3.3	301
178	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Research, 2009, 69, 1302-1313.	0.4	1,067
179	Ajuba: a new microtubuleâ€associated protein that interacts with BUBR1 and Aurora B at kinetochores in metaphase. Biology of the Cell, 2009, 101, 221-240.	0.7	17
180	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Research, 2009, 11, R23.	2.2	74

#	Article	IF	Citations
181	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	0.6	264
182	Reasons for breast cancer heterogeneity. Journal of Biology, 2008, 7, 6.	2.7	67
183	How basal are tripleâ€negative breast cancers?. International Journal of Cancer, 2008, 123, 236-240.	2.3	384
184	Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogÃ©nÃ©tique hÃ©matologique. Leukemia, 2008, 22, 1567-1575.	3.3	64
185	Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene, 2008, 27, 5359-5372.	2.6	107
186	NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia, 2008, 22, 663-665.	3.3	57
187	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes. BMC Cancer, 2008, 8, 299.	1.1	109
188	Sixteenâ€“Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, 2008, 68, 767-776.	0.4	105
189	Cancer Stem Cells in Breast: Current Opinion and Future Challenges. Pathobiology, 2008, 75, 75-84.	1.9	169
190	Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Molecular and Cellular Proteomics, 2008, 7, 1420-1433.	2.5	74
191	Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Research, 2007, 67, 11565-11575.	0.4	254
192	New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. Haematologica, 2007, 92, 262-263.	1.7	12
193	ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell, 2007, 1, 555-567.	5.2	3,550
194	Breast cancer genomics: real-time use. Lancet Oncology, The, 2007, 8, 1045-1047.	5.1	3
195	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene, 2007, 26, 298-307.	2.6	81
196	Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. Leukemia, 2007, 21, 2359-2362.	3.3	11
197	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer, 2007, 7, 73.	1.1	134
198	Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genetics and Cytogenetics, 2007, 176, 80-88.	1.0	26

#	Article	IF	Citations
199	Proteomics of Breast Cancer. Molecular and Cellular Proteomics, 2006, 5, 1772-1786.	2.5	72
200	Gene Expression Profiling and Clinical Outcome in Breast Cancer. OMICS A Journal of Integrative Biology, 2006, 10, 429-443.	1.0	60
201	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Research, 2006, 66, 4636-4644.	0.4	273
202	Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene, 2006, 25, 981-989.	2.6	112
203	Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene, 2006, 25, 2273-2284.	2.6	494
204	Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers. Clinical Cancer Research, 2006, 12, 4533-4544.	3.2	121
205	Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines. British Journal of Cancer, 2005, 92, 382-388.	2.9	8
206	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. Molecular Cancer Research, 2005, 3, 655-667.	1.5	201
207	Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer. Cancer Research, 2005, 65, 2170-2178.	0.4	229
208	How to best classify breast cancer: Conventional and novel classifications (Review). International Journal of Oncology, 2005, 27, 1307.	1.4	17
209	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Research, 2005, 65, 767-79.	0.4	148
210	Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Research, 2004, 64, 8558-8565.	0.4	177
211	A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1/Neuregulin 1/Heregulin Gene. Cancer Research, 2004, 64, 6840-6844.	0.4	185
212	Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. British Journal of Haematology, 2004, 125, 601-604.	1.2	24
213	Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene, 2004, 23, 2564-2575.	2.6	117
214	Aurora B -TACC1 protein complex in cytokinesis. Oncogene, 2004, 23, 4516-4522.	2.6	43
215	Immunophenotypic analysis of inflammatory breast cancers: identification of anâ€˜inflammatory signatureâ€™. Journal of Pathology, 2004, 202, 265-273.	2.1	180
216	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1gene. Genes Chromosomes and Cancer, 2003, 37, 333-345.	1.5	56

#	Article	IF	Citations
217	TACC1â€“chTOGâ€“Aurora A protein complex in breast cancer. Oncogene, 2003, 22, 8102-8116.	2.6	99
218	Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncology, The, 2003, 4, 639-642.	5.1	57
219	A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. International Journal of Molecular Medicine, 2003, 12, 423-8.	1.8	14
220	Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal of Pathology, 2002, 161, 1223-1233.	1.9	144
221	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene, 2002, 21, 5619-5630.	2.6	73
222	Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. Lancet Oncology, The, 2001, 2, 674-682.	5.1	69
223	The ERBB2/HER2 Receptor Differentially Interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 Domain Proteins. Journal of Biological Chemistry, 2001, 276, 15256-15263.	1.6	80
224	MOZ is fused top300 in an acute monocytic leukemia with t(8;22). , 2000, 28, 138-144.		157
225	The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1. Blood, 1999, 93, 1381-1389.	0.6	187
226	A case of inv(8)(p11q24) associated with acute myeloid leukemia involves theMOZ andCBP genes in a masked t(8;16). , 1999, 26, 161-165.		25
227	Hypothesis: more mutations to cure cancer?. Oncology Reports, 1999, 6, 1189-90.	1.2	2
228	Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. , 1996, 15, 191-194.		20
229	FGFRI andPLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers. Genes Chromosomes and Cancer, 1993, 7, 219-226.	1.5	158